New blood test may predict immunotherapy success in cancer patients
NCT ID NCT02840058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether measuring specific immune responses (anti-telomerase T cells) in the blood can help predict how well cancer patients will respond to immunotherapy drugs like anti-PD1/PDL1. Researchers enrolled 295 adults with advanced or metastatic cancer who were about to start such treatment. The goal was to see if these immune markers could serve as a tool to forecast treatment effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Nord Franche-Comté
Montbéliard, 25200, France
-
Hôpital Saint-Louis - APHP
Paris, France
-
Institut Paoli Calmette
Marseille, France
-
University Hospital of Besançon
Besançon, 25000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?